Novo Nordisk and Microsoft Collaborate to Accelerate Drug Discovery Through AI
2022年9月12日 - 8:42PM
Dow Jones News
By Dominic Chopping
Danish pharmaceutical company Novo Nordisk AS said Monday that
it has entered a new strategic collaboration with Microsoft Corp.
that seeks to accelerate drug discovery and development by using
big data and artificial intelligence.
Through the partnership, Microsoft is providing AI technology,
foundational science models and expertise and is working alongside
Novo Nordisk's data scientists and domain experts to accelerate
Novo Nordisk's research and development.
AI models arising from the collaboration will be applied to a
range of use case, with the first two already in execution, it
said.
"Together, we are on a path to enable faster and scaled use of
AI in drug discovery, ultimately leading to more breakthrough
innovations and efficiency gain to better serve the needs of
patients," Lars Fogh Iversen, Novo Nordisk's senior vice president
of digital science & innovation, said.
Write to Dominic Chopping at dominic.chopping@wsj.com
(END) Dow Jones Newswires
September 12, 2022 07:27 ET (11:27 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Microsoft (NASDAQ:MSFT)
過去 株価チャート
から 3 2024 まで 4 2024
Microsoft (NASDAQ:MSFT)
過去 株価チャート
から 4 2023 まで 4 2024
